-
1
-
-
3242877381
-
Immunogenicity of interferon beta: Differences among products
-
Bertolotto A, Deisenhammer F, Gallo P, et al: Immunogenicity of interferon beta: differences among products. J Neurol 2004; 251(suppl 2): II15-II24.
-
(2004)
J Neurol
, vol.251
, Issue.SUPPL. 2
-
-
Bertolotto, A.1
Deisenhammer, F.2
Gallo, P.3
-
2
-
-
0037465461
-
Persistent neutralizing antibodies abolish the interferon β bioavailabity in MS patients
-
Bertolotto A, Gilli F, Sala A, et al: Persistent neutralizing antibodies abolish the interferon β bioavailabity in MS patients. Neurology 2003; 60: 634-639.
-
(2003)
Neurology
, vol.60
, pp. 634-639
-
-
Bertolotto, A.1
Gilli, F.2
Sala, A.3
-
3
-
-
0005489101
-
-
The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894
-
The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
-
-
-
-
4
-
-
0035954361
-
PRISMS-4: Long-term efficacy of interfero-β-1a in relapsing MS
-
PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group
-
PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group: PRISMS-4: long-term efficacy of interfero-β-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
-
(2001)
Neurology
, vol.56
, pp. 1628-1636
-
-
-
5
-
-
22044450811
-
Neutralizing antibodies and efficacy of interferon β-1a: A 4-year controlled study
-
Kappos L, Clanet M, Sandberg-Wollheim M, et al: Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
-
(2005)
Neurology
, vol.65
, pp. 40-47
-
-
Kappos, L.1
Clanet, M.2
Sandberg-Wollheim, M.3
-
6
-
-
22044436956
-
Interferon β-1a in MS: Results following development of neutralizing antibodies in PRISMS
-
Francis GS, Rice GP, Alsop JC: Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
-
(2005)
Neurology
, vol.65
, pp. 48-55
-
-
Francis, G.S.1
Rice, G.P.2
Alsop, J.C.3
-
7
-
-
10744225329
-
Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing - remitting multiple sclerosis
-
Sorensen PS, Ross C, Clemmesen KM, et al: Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing - remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
-
(2003)
Lancet
, vol.362
, pp. 1184-1191
-
-
Sorensen, P.S.1
Ross, C.2
Clemmesen, K.M.3
-
8
-
-
27744509228
-
Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis
-
Sorensen PS, Deisenhammer F, Duda P, et al: Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
-
(2005)
Eur J Neurol
, vol.12
, pp. 817-827
-
-
Sorensen, P.S.1
Deisenhammer, F.2
Duda, P.3
-
9
-
-
27844448644
-
Can the course of multiple sclerosis be modified?
-
Coles A: Can the course of multiple sclerosis be modified? Pract Neurol 2005; 5: 278-287.
-
(2005)
Pract Neurol
, vol.5
, pp. 278-287
-
-
Coles, A.1
-
10
-
-
34147167957
-
Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis
-
Goodin DS, Hurwitz BJ, Noronha A: Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007; 35: 173-187.
-
(2007)
J Int Med Res
, vol.35
, pp. 173-187
-
-
Goodin, D.S.1
Hurwitz, B.J.2
Noronha, A.3
-
11
-
-
39149099154
-
Neutralizing antibodies to interferon 1b are not associated with disease worsening in multiple sclerosis
-
Farrel R, Bendtzen K, Berlotto A, et al: Neutralizing antibodies to interferon 1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2008; 36: 204-208.
-
(2008)
J Int Med Res
, vol.36
, pp. 204-208
-
-
Farrel, R.1
Bendtzen, K.2
Berlotto, A.3
-
12
-
-
34247092348
-
Interferon beta preparations for treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
-
Sominada A, Rot U, Suoniemi M, et al: Interferon beta preparations for treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007; 13: 208-214.
-
(2007)
Mult Scler
, vol.13
, pp. 208-214
-
-
Sominada, A.1
Rot, U.2
Suoniemi, M.3
-
13
-
-
0022555790
-
Quantitation of neutralization of interferon by antibody
-
Kawade Y: Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558-573.
-
(1986)
Methods Enzymol
, vol.119
, pp. 558-573
-
-
Kawade, Y.1
-
14
-
-
37749040878
-
In vivo bioactivity of interferon beta in multiple sclerosis patients with neutralising antibodies is titre-dependent
-
Sominada A, Hillert J, Fogdell-Hahn A: In vivo bioactivity of interferon beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 57-62.
-
(2008)
J Neurol Neurosurg Psychiatry
, vol.79
, pp. 57-62
-
-
Sominada, A.1
Hillert, J.2
Fogdell-Hahn, A.3
-
15
-
-
33750990488
-
Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS
-
Sorensen PS, Tscherning T, Mathiesen HK, et al: Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS. Neurology 2006; 647: 1681-1683.
-
(2006)
Neurology
, vol.647
, pp. 1681-1683
-
-
Sorensen, P.S.1
Tscherning, T.2
Mathiesen, H.K.3
-
16
-
-
0035849496
-
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results
-
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group
-
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504.
-
(2001)
Neurology
, vol.56
, pp. 1496-1504
-
-
-
17
-
-
20144382021
-
Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis
-
Rio J, Porcel J, Tellez N, et al: Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis. Mult scler 2005; 11: 306-309.
-
(2005)
Mult scler
, vol.11
, pp. 306-309
-
-
Rio, J.1
Porcel, J.2
Tellez, N.3
-
18
-
-
0037181634
-
Every-other-day interferon beta-1b versus once-weekly interferon-beta 1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN)
-
Durelli L, Verdun E, Barbero P, et al: Every-other-day interferon beta-1b versus once-weekly interferon-beta 1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
-
(2002)
Lancet
, vol.359
, pp. 1453-1460
-
-
Durelli, L.1
Verdun, E.2
Barbero, P.3
-
19
-
-
0037180479
-
Randomized, comparative study of interferon 1a regimens in MS. The EVIDENCE Trial
-
Panitch H, Goodin DS, Francis G, et al: Randomized, comparative study of interferon 1a regimens in MS. The EVIDENCE Trial. Neurology 2002; 59: 1496-1506.
-
(2002)
Neurology
, vol.59
, pp. 1496-1506
-
-
Panitch, H.1
Goodin, D.S.2
Francis, G.3
-
20
-
-
0034702233
-
A comparison of observational studies and randomized, controlled trials
-
Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 200; 342: 1878-1886.
-
N Engl J Med
, vol.200
, Issue.342
, pp. 1878-1886
-
-
Benson, K.1
Hartz, A.J.2
|